Relating to abortion, including civil liability for the manufacture and provision of abortion-inducing drugs, exemptions from the Texas Citizens Participation Act and Religious Freedom Restoration Act, authorizing civil and qui tam actions, amendments to the fee-shifting statute governing abortion litigation, immunity defenses and limits on state-court jurisdiction and relief, the parens patriae standing of the attorney general, and the jurisdiction of the Fifteenth Court of Appeals; providing for severability.

89th Legislature, 2nd Called Session (2025) Introduced by Brian Birdwell and 13 co-sponsors

Texas bill creating civil liability and private enforcement (including citizen lawsuits) for manufacturing and providing abortion-inducing drugs, removing standard legal defenses and modifying fee rules.

Co-author authorized

#attorneygeneral(v2811) #abortion(i0005) #computers&software(s2425) #civilremedies&liabilities(i0065) #courts--civilprocedure(i0135) #crimes--againstmorals(i0180) #crimes--miscellaneous(i0200) #electronicinformationsystems(i0311) #fifteenthcourtofappeals(vm34v) #mailorder(s0386) #medicine&prescriptiondrugs(s7338) #pregnancy&childbirth(s0294) #statutesoflimitations(s0065) #woman&childprotectionact(p26oy)

Legislative bill overview

SB 7 establishes civil liability mechanisms for the manufacture and provision of abortion-inducing drugs in Texas. The bill creates both private civil actions and qui tam (citizen lawsuit) provisions, removes certain legal defenses under the Texas Citizens Participation Act and Religious Freedom Restoration Act, and modifies fee-shifting rules in abortion litigation. It grants the Texas Attorney General parens patriae standing (authority to sue on behalf of the state) regarding abortion-inducing drugs.

Why is this important

This bill would significantly expand private enforcement mechanisms beyond criminal law, allowing any Texas citizen to sue those involved in providing medication abortion. It represents an extension of Texas's existing enforcement framework (like SB 8's civil liability for abortion providers) into the pharmaceutical supply chain. The removal of standard legal defenses and fee-shifting modifications could create substantial financial and legal exposure for manufacturers, distributors, and providers.

Potential points of contention

Constitutional challenges: Previous abortion enforcement bills have faced federal court challenges on due process and First Amendment grounds; similar litigation could apply here

Definition and scope issues: The bill's definition of "abortion-inducing drugs" and what constitutes "provision" could be interpreted broadly or narrowly, affecting pharmacists, telehealth providers, and shipping companies

Fee-shifting and access to courts: Modified fee provisions could discourage legal defenses while incentivizing litigation, raising concerns about chilling effects on legitimate healthcare practice

Federalism conflicts: Federal law (REMS program, FDA approvals) governs medication abortion; state enforcement may conflict with federal regulatory authority

Private enforcement vs. due process: Qui tam provisions allow private citizens with financial incentives to initiate cases, raising fairness concerns versus government-controlled prosecution